Quetiapine for the continuation treatment of bipolar depression: Naturalistic prospective case series from the Stanley Bipolar Treatment Network

International Clinical Psychopharmacology

Volumn 22, Issue 6, 2007, Pages 376-381

  Suppes, Trisha ^a   Kelly, Dorothy I ^a   Keck Jr , Paul E ^b   McElroy, Susan L ^b   Altshuler, Lori L ^c   Mintz, Jim ^c   Frye, Mark A ^d   Nolen, Willem A ^e   Luckenbaugh, David A ^f   Post, Robert M ^g   Leverich, Gabriele S ^h   Kupka, Ralph W ⁱ   Grunze, Heinz ⁱ  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Mayo Clinic   (United States)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f University Medical Center Groningen ^*

^g PENN STATE COLLEGE OF MEDICINE   (United States)

^h NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

ⁱ UNIVERSITY OF MUNICH   (Germany)

Author keywords

Bipolar depression; Bipolar disorder; Cycling; Quetiapine

Indexed keywords

CARBAMAZEPINE; CITALOPRAM; CLONAZEPAM; ESTROGEN; FLUVOXAMINE; GABAPENTIN; LAMOTRIGINE; LEVOTHYROXINE; LIOTHYRONINE; LITHIUM; METHYLPHENIDATE; NEFAZODONE; OMEGA 3 FATTY ACID; OXAZEPAM; PAROXETINE; PSYCHOTROPIC AGENT; QUETIAPINE; REBOXETINE; RISPERIDONE; SERTRALINE; THIORIDAZINE; TOPIRAMATE; TRAZODONE; VALPROIC ACID; ZOLPIDEM;

ADULT; ARTICLE; BIPOLAR DEPRESSION; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MANIA; MEDICAL RECORD; MOOD DISORDER; OPEN STUDY; OUTCOME ASSESSMENT; OUTPATIENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DATABASES, FACTUAL; DEPRESSION; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; FRUCTOSE; HUMANS; LITHIUM; MALE; MIDDLE AGED; MOOD DISORDERS; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; TRIAZINES;

EID: 34948860033     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e3281c55f63     Document Type: Article

References (32)

1. Angst F, Stassen HH, Clayton PJ, Angst J (2002). Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord 68:167-181.
2. Calabrese JR, Keck PE Jr, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, et al. (2005). A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 162:1351-1360.
3. First MB, Spitzer RL, Gibbon M, Williams JBW (1997). Structured clinical interview for DSM-IV axis I disorders-clinician version (SCID-CV). Washington, District of Columbia: American Psychiatric Press.
4. Ghaemi SN, Sachs GS (1997). Long-term risperidone treatment in bipolar disorder: 6-month follow-up. Int Clin Psychopharm 12:333-338.
5. Ghaemi SN, Hsu DJ, Rosenquist KJ, Katzow JJ, Goodwin R (2004). Long-term observational comparison of risperidone and olanzapine in bipolar disorder. Ann Clin Psychiatry 16:69-73.
6. Hardoy MC, Garofalo A, Carpiniello B, Calabrese JR, Carta MG (2005). Combination quetiapine therapy in the long-term treatment of patients with bipolar I disorder. Clin Pract Epidemiol Mental Health 1:online (http://www.cpementalhealth.com/content/1/1/7).
7. Hirschfeld RM, Lewis L, Vornik LA (2002). Perceptions and impact of bipolar disorder: how far have we really come? Results of the National Depressive and Manic-Depressive Association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry 64:161-174.
8. Judd LL, Akiskal HS (2003). The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. J Affective Disord 73:123-131.
9. Keck PE Jr, Perlis RH, Otto MW, Carpenter D, Ross R, Docherty JP (2004). The expert consensus guideline series: treatment of bipolar disorder 2004. In: Postgraduate Medicine Special Report. pp. 1-120.
10. Keck PE Jr, Calabrese JR, McQuade RD, Carson WH, Carlson BX, Rollin LM, et al. (2006). A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 67:626-637.
11. Leverich GS, Post RM (1998). Life charting of affective disorders. CNS Spectrums 3:21-37.
12. Leverich GS, Nolen WA, Rush AJ, McElroy SL, Keck PE, Denicoff KD, et al. (2001). The Stanley Foundation Bipolar Treatment Outcome Network. I. Longitudinal methodology. J Affective Disord 67:33-44.
13. Marchand WR, Wirth L, Simon C (2004). Quetiapine adjunctive and monotherapy for pediatric bipolar disorder: a retrospective chart review. J Child Adolesc Psychopharm 14:405-411.
14. Milev R, Abraham G, Zaheer J (2006). Add-on quetiapine for bipolar depression: a 12-month open-label trial. Can J Psychiatry 51:523-530.
15. Pae C-U, Kim T-S, Kim J-J, Lee S-J, Lee C-U, Lee C, et al. (2005). Long-term treatment of adjunctive quetiapine for bipolar mania. Progr Neuro-Psychopharm Biol Psychiatry 29:763-766.
16. Sajatovic M, Brescan DW, Perez DE, DiGiovanni SK, Hattab H, Ray JB, et al. (2001). Quetiapine alone and added to a mood stabilizer for serious mood disorders. J Clin Psychiatry 62:728-732.
17. Sanger TM, Grundy SL, Gibson PJ, Namjoshi MA, Greaney MG, Tohen MF (2001). Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study. J Clin Psychiatry 62:273-281.
18. Sokolski KN, Denson TF (2003). Adjunctive quetiapine in bipolar patients partially responsive to lithium or valproate. Progr Neuro-Psychopharm Biol Psychiatry 27:863-866.
19. Suppes T, Webb A, Paul B, Carmody T, Kraemer H, Rush AJ (1999). Clinical outcome in a randomized 1-year trial of clozapine vs. treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry 156:1164-1169.
20. Suppes T, Leverich GS, Keck PE, Nolen WA, Denicoff KD, Altshuler LL, et al. (2001). The Stanley Foundation Bipolar Treatment Outcome Network. II. Demographics and illness characteristics of the first 261 patients. J Affective Disord 67:45-59.
21. Suppes T, McElroy SL, Keck PE, Altshuler L, Frye MA, Grunze H, et al. (2004). Use of quetiapine in bipolar disorder: a case series with prospective evaluation. Int Clin Psychopharm 19:173-174.
22. Suppes T, Dennehy EB, Hirschfeld RMA, Altshuler LL, Bowden CL, Calabrese JR, et al. (2005). The Texas Implementation of Medication Algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry 66:870-886.
23. Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, et al. (2006). Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (The BOLDER II Study) (in press).
24. Tohen M, Ketter TA, Zarate CA, Suppes T, Frye M, Altshuler L, et al. (2003). Olanzapine vs. divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry 160:1263-1271.
25. Tohen M, Chengappa KN, Suppes T, Baker RW, Zarate CA, Bowden CL, et al. (2004). Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser vs. mood stabiliser alone. Br J Psychiatry 184:337-345.
26. Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, et al. (2005). Olanzapine vs. lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 162:1281-1290.
27. Tohen M, Calabrese JR, Sachs GS, Banov MD, Detke HC, Risser R, et al. (2006). Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 163:247-256.
28. Vieta E, Reinares M, Corbella B, Benabarre A, Gilaberte I, Colom F, et al. (2001a). Olanzapine as long-term adjunctive therapy in treatment-resistant bipolar disorder. J Clin Psychopharm 21:469-473.
29. Vieta E, Goikolea JM, Corbella B, Benabarre A, Reinares M, Martinez G, et al. (2001b). Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: results from a 6-month, multicenter, open study. J Clin Psychiatry 62:818-825.
30. Vieta E, Parramon G, Padrell E, Nieto E, Martinez-Aran A, Corbella B, et al. (2002). Quetiapine in the treatment of rapid cycling bipolar disorder. Bipolar Disord 4:335-340.
31. Yatham LN, Kennedy SH, O'Donovan C, Parikh S, MacQueen G, McIntyre R, et al. (2005). Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord 7:5-69.
32. Yatham LN, Kennedy SH, O'Donovan C, Parikh S, MacQueen G, McIntyre R, et al. (2006). Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: Update 2007. Bipolar Disord 8:721-739.